Please use this identifier to cite or link to this item:
|Title:||The renin-angiotensin system and malignancy.||Austin Authors:||Ager, Eleanor I;Neo, Jaclyn;Christophi, Christopher||Affiliation:||Department of Surgery, Austin Health, University of Melbourne, Heidelberg, Victoria 3084, Australia||Issue Date:||16-Jul-2008||Publication information:||Carcinogenesis 2008; 29(9): 1675-84||Abstract:||The renin-angiotensin system (RAS) is usually associated with its systemic action on cardiovascular homoeostasis. However, recent studies suggest that at a local tissue level, the RAS influences tumour growth. The potential of the RAS as a target for cancer treatment and the suggested underlying mechanisms of its paracrine effects are reviewed here. These include modulation of angiogenesis, cellular proliferation, immune responses and extracellular matrix formation. Knowledge of the RAS has increased dramatically in recent years with the discovery of new enzymes, peptides and feedback mechanisms. The local RAS appears to influence tumour growth and metastases and there is evidence of tissue- and tumour-specific differences. Recent experimental studies provide strong evidence that drugs that inhibit the RAS have the potential to reduce cancer risk or retard tumour growth and metastases. Manipulation of the RAS may, therefore, provide a safe and inexpensive anticancer strategy.||Gov't Doc #:||18632755||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10641||DOI:||10.1093/carcin/bgn171||Journal:||Carcinogenesis||URL:||https://pubmed.ncbi.nlm.nih.gov/18632755||Type:||Journal Article||Subjects:||Angiotensin-Converting Enzyme Inhibitors.therapeutic use
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.